Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Share News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 315.00
Bid: 315.00
Ask: 316.00
Change: 0.00 (0.00%)
Spread: 1.00 (0.317%)
Open: 327.00
High: 327.00
Low: 311.50
Prev. Close: 315.00
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

SMALL-CAP WINNERS & LOSERS: Record down as managed assets decline

Fri, 20th Oct 2023 10:02

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Friday.

----------

SMALL-CAP - WINNERS

----------

Regional REIT Ltd, up 4.4% at 27.52 pence, 12-month range 25.57p-69.60p. This is after the London-based real estate investment trust's share price falls 2.0% in the last five days and 49% in the last six months. Last month, it reported a first half pretax loss of GBP12.1 million from a profit of GBP28.3 million a year earlier.

----------

Oxford BioMedica PLC, up 3.7% at 260.26p, 12-month range 236.50p-575.00p. This is after the Oxfordshire, England-based gene and cell therapy group's share price falls 7.8% in the last five days and 39% in the last six months. Last month, it reported that its first half pretax loss widened to GBP52.3 million from GBP27.4 million, although shares rose on noting it was in exclusive talks to buy ABL Europe from Institut Merieux SA for EUR15 million.

----------

SMALL-CAP - LOSERS

----------

Record PLC, down 4.9% at 69.4p, 12-month range 68.12p-102.00p. The currency and derivatives manager said that plans for diversification are progressing well, despite seeing assets under management decline in the second quarter. For the three months ended September 30, it says assets under management equivalents fell to USD84.5 million, from USD86.4 million at the end of June. Dynamic hedging assets under management fall 5.2% to USD14.5 billion from USD15.3 billion in the first quarter, while passive hedging assets fall 1.8% to USD60.5 billion from USD61.6 billion. "Our plans for diversification through our asset management and digital asset businesses continue to progress well, albeit in places more gradually than initially envisaged, and I look forward to giving more detail on our strategic progress at our forthcoming half-year results in November," says Chief Executive Leslie Hill.

----------

Sabre Insurance Group PLC, down 4.3% at 145.5p, 12-month range 81.90p-168.00p. Barclays raises its price target for the Dorking, England-based motor insurance underwriter to 171p from 157p, rating the stock at 'overweight'. Sabre Insurance shares were up 3.3% at 155.00p in London on Thursday around noon, after celebrating a sharp increase in gross written premiums in the last nine months, despite Motorcycle premiums plummeting. It also raised its full-year guidance. Gross written premiums increased 20% in the nine months ended September 30, to GBP162.2 million from GBP135.7 million. In 2022, they totalled GBP171.3 million.

----------

By Greg Rosenvinge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
1 Dec 2020 14:29

UK DIRECTOR DEALINGS SUMMARY: Oxford BioMedica Non-Exec And Wife Sell

UK DIRECTOR DEALINGS SUMMARY: Oxford BioMedica Non-Exec And Wife Sell

Read more
9 Nov 2020 10:01

Oxford BioMedica, PhoreMost Team For Next-Gen Cell Therapy Development

Oxford BioMedica, PhoreMost Team For Next-Gen Cell Therapy Development

Read more
9 Nov 2020 09:16

Oxford Biomedica strikes collaboration agreement with PhoreMost

(Sharecast News) - Gene and cell therapy group Oxford Biomedica has inked a discovery collaboration agreement with UK-based biopharmaceutical company PhoreMost.

Read more
4 Nov 2020 09:40

UK BROKER RATINGS SUMMARY: BofA Raises Lloyds; Liberum Likes Landsec

UK BROKER RATINGS SUMMARY: BofA Raises Lloyds; Liberum Likes Landsec

Read more
30 Oct 2020 08:47

Oxford Biomedica partner delays Parkinson's disease treatment trial

(Sharecast News) - Gene and cell therapy group Oxford Biomedica said on Friday that partner Axovant Gene Therapies had pushed out the start date for its trial into a Parkinson's disease treatment.

Read more
23 Oct 2020 15:15

UK DIRECTOR DEALINGS SUMMARY: Liontrust Chiefs Bank GBP1.6 Million

UK DIRECTOR DEALINGS SUMMARY: Liontrust Chiefs Bank GBP1.6 Million

Read more
6 Oct 2020 14:19

Oxford BioMedica Notes Positive Follow-Up Data From AXO-Lenti-PD

Oxford BioMedica Notes Positive Follow-Up Data From AXO-Lenti-PD

Read more
6 Oct 2020 09:44

Another Manufacturing Suite At Oxford Biomedica's Oxbox Gets Approval

Another Manufacturing Suite At Oxford Biomedica's Oxbox Gets Approval

Read more
6 Oct 2020 07:55

LONDON BRIEFING: BHP To Increase Stake In Gulf Of Mexico Development

LONDON BRIEFING: BHP To Increase Stake In Gulf Of Mexico Development

Read more
6 Oct 2020 07:43

LONDON MARKET PRE-OPEN: Watches Of Switzerland Ups Full-Year Guidance

LONDON MARKET PRE-OPEN: Watches Of Switzerland Ups Full-Year Guidance

Read more
6 Oct 2020 07:03

Oxford Biomedica new manufacturing suite approved

(Sharecast News) - Oxford Biomedica said it had received government approval for a fourth manufacturing suite within its Oxbox facility which will be used to develop a potential Covid-19 vaccine.

Read more
17 Sep 2020 10:43

Oxford Biomedica Burns Bright Amid AstraZeneca Vaccine Deal

Oxford Biomedica Burns Bright Amid AstraZeneca Vaccine Deal

Read more
17 Sep 2020 08:35

LONDON MARKET OPEN: Stocks Tumble In US Fed's Wake And Ahead Of BoE

LONDON MARKET OPEN: Stocks Tumble In US Fed's Wake And Ahead Of BoE

Read more
17 Sep 2020 07:52

LONDON MARKET PRE-OPEN: Next Raises Full-Year Profit Outlook

LONDON MARKET PRE-OPEN: Next Raises Full-Year Profit Outlook

Read more
17 Sep 2020 07:01

Oxford Biomedica sees swing to FY profit on Covid vaccine hopes

(Sharecast News) - Drugs maker Oxford Biomedica, which has partnered with pharma giant AstraZeneca to develop a Covid-19 vaccine, said it expected higher second half revenues to push it to a low-to-single digit full year profit.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.